Europe 1 with AFP 11:29 am, December 02, 2021
The European regulator announced Thursday to launch the accelerated examination of the anti-Covid vaccine by the Franco-Austrian laboratory Valneva, with which the European Commission has reached an agreement of up to 60 million doses by 2023.
The European Medicines Agency (EMA) announced on Thursday the launch of the accelerated review of the anti-Covid vaccine by the Franco-Austrian laboratory Valneva, with which the European Commission has reached an agreement of up to 60 million doses of 'by 2023.
"The EMA's Committee for Medicinal Products for Human Use (CHMP) has started a continuous review of VLA2001, an anti-Covid-19 vaccine developed by Valneva," the European regulator announced in a press release, specifying that it could not yet estimate when an authorization decision could be made.
>> More information to follow